TKT Replagal Decision On New Trial Expected In Four Months
Executive Summary
Transkaryotic Therapies will decide this summer after meeting with FDA whether to conduct additional clinical trials with its Fabry disease agent Replagal
You may also be interested in...
TKT Replagal Approval Path Will Begin With Request For Protocol Assessment
Transkaryotic Therapies hopes to begin discussion on a potential approval pathway for the Fabry disease agent Replagal in November via a request for an FDA special protocol assessment, CEO Michael Astrue said during an Oct. 29 conference call
TKT Replagal Approval Path Will Begin With Request For Protocol Assessment
Transkaryotic Therapies hopes to begin discussion on a potential approval pathway for the Fabry disease agent Replagal in November via a request for an FDA special protocol assessment, CEO Michael Astrue said during an Oct. 29 conference call
TKT Hunter’s syndrome product
TKT estimates market for Hunter's syndrome product I2S (currently under development) is $300 mil., not $30 mil. as incorrectly reported by "The Pink Sheet" (1May 18, p. 12)...